用促甲状腺激素释放激素类似物DN-1417治疗肌萎缩侧索硬化症。
Treatment of amyotrophic lateral sclerosis with the TRH analog DN-1417.
作者信息
Hawley R J, Kratz R, Goodman R R, McCutchen C B, Sirdofsky M, Hanson P A
出版信息
Neurology. 1987 Apr;37(4):715-7. doi: 10.1212/wnl.37.4.715.
Thyrotropin-releasing hormone has been reported to increase strength in patients with amyotrophic lateral sclerosis (ALS). DN-1417 is an analog of thyrotropin-releasing hormone, which has less endocrinologic activity, but more anterior horn cell stimulating effect (with no "autorefractory state"). However, 2 mg DN-1417, IM twice a day for 1 month in an open-label trial, produced no objective improvement of strength in nine patients with ALS. No patient entered the double-blind, placebo-controlled phase of the trial.
据报道，促甲状腺激素释放激素可增强肌萎缩侧索硬化症（ALS）患者的肌力。DN - 1417是促甲状腺激素释放激素的类似物，其内分泌活性较低，但对前角细胞的刺激作用更强（无“自身不应期”）。然而，在一项开放标签试验中，9例ALS患者每天两次、每次2毫克肌内注射DN - 1417，持续1个月，肌力并未出现客观改善。没有患者进入该试验的双盲、安慰剂对照阶段。
Zotero 插件